NCT03569280View on ClinicalTrials.gov

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

January 10, 2023

Study Completion Date

June 15, 2023

Conditions
Castration-Resistant Prostate Cancer
Interventions
COMBINATION_PRODUCT

Enzalutamide or Abiraterone or Apalutamid

Antitumor treatment

Trial Locations (3)

11776

North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, Port Jefferson Station

22903

University of Virginia Cancer Center, Charlottesville

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

Sponsors
All Listed Sponsors
lead

Kangpu Biopharmaceuticals, Ltd.

INDUSTRY

NCT03569280 - Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | Biotech Hunter | Biotech Hunter